NDT Advance Access published online on April 8, 2009
Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfp162
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: the Symphony pharmacokinetic substudy
1 Hospital Universitari de Bellvitge, Barcelona, Spain 2 Lund University, Malmö, Sweden 3 Mamelok Consulting, Palo Alto, CA, USA 4 Hospital Clinic i Provincial, Barcelona 5 HU La Fe, Valencia 6 Hospital Virgen del Rocio, Sevilla 7 Hospital Universitario de Canarias, Tenerife, Spain 8 University of Leuven, Leuven, Belgium
Correspondence and offprint requests to: Josep M. Grinyó; E-mail: jgrinyo{at}bellvitgehospital.cat
 |
Abstract |
|---|
Background. Exposure to mycophenolic acid (MPA), the primary active metabolite of mycophenolate mofetil (MMF), is correlated with therapeutic efficacy of MMF but varies depending on the concomitantly administered immunosuppressive drugs.
Methods. A 3-month pharmacokinetic substudy of the prospective, randomized, multicentre, open-label Symphony study was performed. Eighty-three adult renal transplant patients received standard-dose cyclosporine, MMF 2 g/day and corticosteroids, or daclizumab induction, MMF 2 g/day and corticosteroids plus low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus. The area under the concentration–time curve (AUC0–12) of MPA and its metabolites between treatment groups was compared. Pharmacokinetic sampling was performed before MMF administration and at 20, 40, 75 min; 2, 3, 6, 8, 10 and 12 h post-dose on Day 7 and Months 1 and 3.
Results. Compared with standard-dose cyclosporine, patients receiving low-dose tacrolimus or low-dose sirolimus had significantly higher AUC0–12 values for MPA at Day 7 and Month 1 and for free MPA at Day 7, and significantly lower AUC0–12 values for 7-O-MPA-glucuronide (MPAG) at Month 1 and for acyl-glucuronide at Months 1 and 3 (P < 0.05). AUC0–12 of MPA and free MPA was significantly greater with low-dose tacrolimus and low-dose sirolimus than with low-dose cyclosporine in the first month (P < 0.05). The ratio of MPA to MPAG exposure was significantly higher in the three low-dose groups than in the standard-dose cyclosporine group (P < 0.05).
Conclusions. Standard- and low-dose cyclosporine reduces the exposure of MPA and free MPA compared to low-dose tacrolimus or low-dose sirolimus in patients given the same dose of MMF.
Keywords: mycophenolate mofetil; mycophenolic acid; mycophenolic acid glucuronide; pharmacokinetics; renal transplantation
Received for publication: 27.10.08
Accepted in revised form: 10. 3.09